Sentence examples for formulation trials from inspiring English sources

Out of twenty formulation trials, eight formulations had all parameters in proven acceptable range.

In the formulation development area, in silico predictive tools and model-based IVIVC approaches supported formulation development and life-cycle management resulting in more successful late stage formulation trials and also regulatory success.

It appears that standard RCTs may not be the most correct method to compare these two types of formulations; trial participants may over-represent patients with a good engagement with healthcare providers and who are more likely to be adherent than patients in naturalistic conditions [ 117].

Such diverse tasks as fuel formulation, clinical trial design and chemical process optimization are solved using experimental designs to combine variables in specific ways, and regression analysis techniques to dissect out the contribution of each variable to the outcome [ 9].

Eli Lilly & Company said yesterday that it had terminated its agreement with Sepracor, a small drug company, to make a new version of the antidepressant drug Prozac after some patients taking the new formulation in clinical trials developed abnormal heart rhythms.

[A1.] Eli Lilly Ends Sepracor Agreement Eli Lilly said that it had terminated its agreement with Sepracor, a small drug company, to make a new version of the antidepressant drug Prozac after some patients taking the new formulation in clinical trials developed abnormal heart rhythms.

Drug discovery and development procedure involves; acquisition, preclinical screening, production and formulation, toxicology, clinical trials, and general medical practice [3].

Hence, QSPR approach saves resources by predicting drug release from an unformulated formulation; avoiding repetitive trials in the development of a new formulation and/or optimization of existing one.

More importantly, and regardless of the formulation type, clinical trials require pre-clinical assays and models to predict the treatment efficacy.

Such measurements could assist in minimizing protein aggregation and in maintaining the consistency in the size distribution and morphology of residual particle populations during formulation development, clinical trials, manufacturing, and storage.

The improved survival of these patients has prompted the formulation of clinical trials in both North America (RTOG 1016) and Europe (DeESCALaTE-HPV) to test the feasibility of de-escalation of therapy to reduce acute and late toxicity.